Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Third national IPA Convention to be held in Indore in April, 2011

     The next Indian Pharmaceutical Association Convention (IPA Convention 2011) will be held at Indore in Madhya Pradesh in April next year. This was announced by the outgoing president of IPA Dr B Suresh at the valedictory session of the IPA Convention 2010 held in Chennai last week.

  • PCI clarifies its notification on MS not specific on NIPER's course

     Entailing the ongoing controversy over the recognition of Master of Pharmacy (MS) programme offered by National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Pharmacy Council of India (PCI) has come out with a clarification that the NIPER's MS programme has not been specifically commented anytime by the council and is not an issue under the consideration of the body.

  • Women With MI Less Likely to Get Cath Procedures

     March 23, 2010 (Atlanta, Georgia) — An unexplained bias against sending women to the cath lab may be the reason women are about twice as likely as men to die within a month of an MI, a study from the European Cardiology Audit and Registration Data Standards (CARDS) data set shows.

  • Piramal Healthcare acquires i-pill brand from Cipla

     Piramal Healthcare and Cipla signed a definitive agreement for purchase of all intellectual property rights in India related to i-pill brand of Cipla. The deal was sealed for an aggregate consideration of Rs 95 crore. i-pill brand features in the top-300 pharmaceutical products and had sales of Rs 30.92 crore as per ORG IMS for the last twelve months.

  • Deaths during clinical trials on rise as India turning as hot destination

    Even as the dust is yet to settle down over the HPV vaccine trial and death of three tribal girls in Andhra Pradesh, records showed that the total number of deaths among the clinical trial subjects, though not officially termed as part of the trials, are on the increase in India.

  • Syngene, Endo Pharmaceuticals in oncology deal

     Bangalore, Mar, 23, 2010: Syngene International, a subsidiary of Biocon has entered into a discovery and development collaboration with Endo Pharmaceuticals, USA to develop novel biological therapeutic molecules against cancer.

    Under the agreement Endo will retain all rights to the molecules developed, while Syngene International will receive research fees, milestone payments and success fees from Endo.

     [adsense:336x280:8701650588]

  • Drug-resistant tuberculosis now at record levels: WHO report

    In some areas of the world, one in four people with tuberculosis (TB) becomes ill with a form of the disease that can no longer be treated with standard drugs regimens, a World Health Organization (WHO) report says.

  • Recession hit West storms into India for clinical research, pharmacovigilance next growth path for CROs

     India’s clinical research organizations (CROs) are set for exponential growth going by the number of assignments which are coming in here. The global economic slowdown which has seriously impacted western world has benefited the Indian clinical research industry. Scores of assignments are pouring in to conduct clinical trials, pharmacovigilance studies and data management works.

  • FDA Temporarily Suspends Use of Rotarix Vaccine

    March 22, 2010 — The US Food and Drug Administration (FDA) announced today viral contamination of GlaxoSmithKline's Rotarix vaccine. The agency is recommending that doctors stop using the vaccine until further investigations are complete.

    An independent academic research team testing the product recently identified porcine circovirus 1 in the vaccine and notified regulators.

  • High-Dose Simvastatin Associated With Increased Risk for Myopathy

     March 19, 2010 — Simvastatin (Zocor, Merck/Schering-Plough Pharmaceuticals), used at the highest approved dose of 80 mg, is associated with an increased risk for myopathy, including rhabdomyolysis, according to the US Food and Drug Administration (FDA).

Subscribe to Pharma News